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OBJECTIVE
Severe hypoglycemia is common in older adults with long-standing type 1 diabe-
tes, but little is known about factors associated with its occurrence.
RESEARCH DESIGN AND METHODS
A case-control study was conducted at 18 diabetes centers in the T1D Exchange
Clinic Network. Participantswere‡60 years oldwith type 1 diabetes for‡20 years.
Case subjects (n = 101) had at least one severe hypoglycemic event in the prior
12 months. Control subjects (n = 100), frequency-matched to case subjects by age,
had no severe hypoglycemia in the prior 3 years. Data were analyzed for cognitive
and functional abilities, social support, depression, hypoglycemia unawareness,
various aspects of diabetes management, C-peptide level, glycated hemoglobin
level, and blinded continuous glucose monitoring (CGM) metrics.
RESULTS
Glycated hemoglobin (mean 7.8% vs. 7.7%) and CGM-measured mean glucose
(175 vs. 175 mg/dL) were similar between case and control subjects. More case
than control subjects had hypoglycemia unawareness: only 11% of case subjects
compared with 43% of control subjects reported always having symptoms asso-
ciated with low blood glucose levels (P < 0.001). Case subjects had greater glucose
variability than control subjects (P = 0.008) and experienced CGM glucose levels
<60 mg/dL for ‡20 min on 46% of days compared with 33% of days in control
subjects (P = 0.10). On certain cognitive tests, case subjects scored worse than
control subjects.
CONCLUSIONS
In older adults with long-standing type 1 diabetes, greater hypoglycemia un-
awareness and glucose variability are associated with an increased risk of severe
hypoglycemia. A study to assess interventions to prevent severe hypoglycemia in
high-risk individuals is needed.
Older adults with type 1 diabetes (T1D) are a growing but underevaluated popula-
tion (1–4). Of particular concern in this age group is severe hypoglycemia, which, in
addition to producing altered mental status and sometimes seizures or loss of
consciousness, can be associatedwith cardiac arrhythmias, falls leading to fractures,
and in some cases, death (5–7). In Medicare beneficiaries with diabetes, hospital-
izations related to hypoglycemia are now more frequent than those for hypergly-
cemia and are associated with high 1-year mortality (6). Emergency department
visits due to hypoglycemia also are common (5). These reports likely underestimate
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the problem of hypoglycemia in older
adults with T1D because they include
individuals with type 2 diabetes in
whom severe hypoglycemic events are
considerably less frequent. In addition,
glucose levels at the time of falls (hip
fractures) and the onset of cardiac
events are frequently unavailable (8).
The T1D Exchange clinic registry
reported a remarkably high frequency
of severe hypoglycemia resulting in sei-
zure or loss of consciousness in older
adults with long-standing T1D (9). One
or more such events during the prior
year was reported by 1 in 5 of 211 par-
ticipants $65 years of age with $40
years’ duration of diabetes (9).
Unlike treatment guidelines in younger
individuals with T1D, which focus on op-
timizing glycated hemoglobin (HbA1c)
levels, treatment approaches for older
adults with T1D often focus on minimiz-
ing hypoglycemia rather than attempt-
ing to achieve low HbA1c levels (10,11).
Despite this approach, data from the
T1D Exchange (9) indicate that severe
hypoglycemia in adults with T1D is as
commonwith higher (.8.0%) HbA1c lev-
els as it is with lower (,7.0%) levels (9).
Despite the high frequency of severe
hypoglycemia in older adults with long-
standing T1D, little information is avail-
able about the factors associated with
its occurrence. We conducted a case-
control study in adults $60 years of
age with T1D of $20 years’ duration to
assess potential contributory factors for
the occurrence of severe hypoglycemia,
including cognitive and functional mea-
surements, social support, depression,
hypoglycemia unawareness, various as-
pects of diabetes management, residual
insulin secretion (as measured by
C-peptide levels), frequency of bio-
chemical hypoglycemia, and glycemic
control and variability.
RESEARCH DESIGN AND METHODS
The study was conducted at 18 diabetes
centers participating in the T1D Ex-
change Clinic Network (12). The centers
are listed in the Supplementary Data.
The study adhered to the tenets of the
Declaration of Helsinki and was ap-
proved by the respective multiple institu-
tional review boards. Study participants
provided written informed consent before
study participation.
Case subjects were required to have
had at least one severe hypoglycemic
event in the prior 12 months, defined
as an event requiring assistance of an-
other person as a result of altered con-
sciousness or confusion, to administer
carbohydrate or glucagon or other re-
suscitative actions. Control subjects
were required to have not had a severe
hypoglycemic event in the past 3 years.
Case and control subjects were fre-
quency matched on clinic and age in
5-year bins. Major eligibility criteria
for case and control subjects included
clinical diagnosis of autoimmune T1D
being treatedwith insulin, age$60 years,
and diabetes duration of$20 years. Ex-
clusion criteria included current use of a
Table 1—Participant characteristics
Case subjects Control subjects
n = 101 n = 100 P value
Sex: women
R
51 (50) 44 (44) 0.36
Agem (years) 68.6 6 6.4 68.0 6 5.9 0.52
60 to ,65 32 (32) 36 (36)
65 to ,70 33 (33) 31 (31)
70 to ,75 19 (19) 20 (20)
$75 17 (17) 13 (13)
Race/ethnicity: non-Hispanic white
R
94 (93) 91 (91) 0.59
T1D durationm (years) 40.5 6 11.6 39.6 6 11.9 0.58
20 to ,30 22 (22) 29 (29)
30 to ,40 28 (28) 22 (22)
40 to ,50 26 (26) 23 (23)
$50 25 (25) 26 (26)
Education*
R
0.62
Less than high school or
high school diploma/GED
14 (14) 11 (11)
Some college/associate or bachelor degree 59 (59) 65 (65)
Master/professional or doctorate degree 27 (27) 23 (23)
Insurance*
R
q 0.35
Government and commercial 35 (35) 37 (37)
Only commercial 26 (26) 34 (34)
Only government 38 (38) 27 (27)
None 1 (1) 2 (2)
Income (annual)*
R
0.41
,$35,000 24 (26) 22 (26)
$35,000 to ,$50,000 12 (13) 9 (11)
$50,000 to ,$100,000 30 (33) 33 (39)
$$100,000 26 (28) 20 (24)
BMI (kg/m2)*Vm 26.9 6 5.0 27.0 6 4.4 0.94
Underweight 3 (3) d
Normal weight 37 (37) 37 (38)
Overweight 34 (34) 36 (37)
Obese 25 (25) 25 (26)
Exercise*‡m (days/week) 6 (4, 7) 5 (4, 7) 0.52
Alcohol use*m (days/month) 3.5 (0, 25) 2.5 (0, 20) 0.64
At least 1 day per month of binge drinkingU
R
6 (6) 3 (3) 0.50
Live alone
R
25 (25) 22 (22) 0.64
Categorical variables are shown as n (%) and continuous variables as mean6 SD or median (25th,
75th percentile).
R
P value obtained from x2 test or Fisher exact test when appropriate.mP value
obtained from t test or Wilcoxon test when appropriate. *Education data missing for 1 case
and 1 control subject; health insurance data missing for 1 case subject; income data missing for
9 case and 16 control subjects; BMI data missing for 2 case and 2 control subjects; exercise data
missing for 2 case subjects; alcohol data missing for 1 case subject. qThe government and
commercial insurance group includes those with government insurance (Medicare, Medigap,
Medicaid, TRICARE, Indian Health Service Plan, State Children’s Health Insurance Program, etc.)
and commercial insurance (commercial, fee-for-service, health maintenance organization,
preferred provider organization, point-of-service) or a single-service plan (e.g., dental, vision,
prescriptions). The only commercial insurance group includes those with commercial insurance
only, and the only government insurance group includes those with government insurance only.
‡Exercise defined as at least 20min of physical activity.UBinge drinking defined as$5 drinks in a
row, within a couple of hours. VBMI is weight in kilograms divided by height in meters2;
underweight defined as BMI,18.5 kg/m2, normal weight defined as BMI 18.5 to,25.0 kg/m2,
overweight defined as BMI 25.0 to ,30.0 kg/m2, and obese defined as BMI $30.0 kg/m2.
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continuous glucose monitor (CGM),
chronic kidney disease stage 4 or 5 (glo-
merular filtration rate ,30 mL/min/
1.73 m2 [if known]), diagnosis of moder-
ate or advanced dementia, serious ill-
ness with life expectancy of ,1 year,
and history of pancreatic transplant.
Testing Procedures
In addition to a standard history includ-
ing information about prior severe hy-
poglycemia and diabetes management
and a physical examination, a battery
of tests were completed at two visits
;2 weeks apart. The cognitive test bat-
tery includedmeasures of general mental
status (Montreal Cognitive Assessment
[13]), psychomotor processing speed
(Symbol Digit Modalities Test [14]), exec-
utive functioning (Trail Making Test–Trail
A and B [15,16]), and verbal memory
(Hopkins Verbal Learning Test–Revised
[17]). Before the cognitive testing,
the blood glucose was checked, and the
testing was deferred to another day if
,70 mg/dL (3.9 mmol/L). Raw scores
were used because there were no signif-
icant differences in demographic factors
between groups.
Fine motor dexterity and speed
(Grooved Pegboard Test [18]), depres-
sion symptoms (Geriatric Depression
Scale Short Form [19]), instrumental ac-
tivities of daily living (Functional Activi-
ties Questionnaire [20]), social support
(Duke Social Support Index [21]), diabe-
tes numeracy (Diabetes Numeracy Test–15
question [22]), visual acuity (Colenbrander
Reading Card [English Continuous Text
Near Vision Card] [23]), and physical
frailty (timed 10-foot walk [24]) were
also assessed.
Diabetes-related questionnaires in-
cluded hypoglycemia unawareness
(Clarke Hypoglycemia Unawareness
Questionnaire [25]), hypoglycemia fear
(Hypoglycemia Fear Survey [26]), and hy-
perglycemia fear (Preferring Hypoglyce-
mia Scale; W.H. Polonsky, personal
communication).
All questionnaires and functional
testing were scored using recom-
mended approaches, except for the
Clarke Questionnaire (Supplementary
Table 1). Because this survey includes
questions regarding recent hypoglyce-
mic events, an overall score would be
invalid; therefore, scores for pertinent
items were tabulated individually. Mea-
surements of HbA1c, random C-peptide,
glucose, and creatinine levels were
performed at a central laboratory.
A SEVEN PLUS CGM (Dexcom, Inc.,
San Diego, CA) in blinded mode (partic-
ipant unable to see the glucose values)
was worn for 14 days (two 7-day sen-
sors) with daily calibration according to
the label. Excluding the data from one
case subject who used acetaminophen
frequently despite instructions to the
contrary (acetaminophen can affect
the accuracy of the Dexcom sensor)
and one control subject with no avail-
able CGM glucose data, the median
(interquartile range) amount of CGM
data was 277 h (235–309) for case sub-
jects and 294 h (255–315) for control
subjects. CGM metrics were computed
overall and separately for daytime (6 A.M.
to midnight) and nighttime (midnight to
6 A.M.). The calculation of proportion of
days with at least one CGM hypoglyce-
mic event (defined as at least 20 min
with CGM glucose values ,60 mg/dL)
was limited to participants with at least
7 days of data.
Statistical Analysis
Characteristics between the case and con-
trol subjects were compared with the x2
test, Fisher exact test, t test, andWilcoxon
test (dependent on variable distribution).
Adjusted regression models were run to
assess the relationship between case-
control status and various clinical factors,
diabetes management factors, CGM data,
and assessments. All statistical analyses
were performed using SAS 9.4 software
(SAS Institute, Cary, NC). All P values are
two-sided. A priori, in view of themultiple
comparisons, only P values ,0.01 were
considered statistically significant.
Table 2—Diabetes management and clinical factors
Case subjects Control subjects
n = 101 n = 100 P value
Pump usex 59 (58) 59 (59) 0.99
Total daily insulinx*Ϯ (units/kg) 0.5 (0.4, 0.7) 0.5 (0.4, 0.6) 0.28
,0.40 20 (23) 27 (29)
0.40 to ,0.60 41 (47) 39 (42)
$0.60 27 (31) 27 (29)
Home blood glucose monitoringxϮ
(times/day)
6 6 3 5 6 2 0.02
0 1 (,1) 0 (0)
1–3 5 (5) 18 (18)
4 21 (21) 24 (24)
5–6 41 (41) 31 (31)
7–9 20 (20) 22 (22)
$10 13 (13) 5 (5)
HbA1c*ϮP, %
(mmol/mol)
7.8 6 1.3
(62.1 6 13.9)
7.7 6 1.1
(60.4 6 12.0)
0.06
,7.0 (,53) 26 (26) 28 (28)
7.0 to ,8.0 (53 to ,64) 31 (31) 36 (36)
8.0 to ,9.0 (64 to ,75) 25 (25) 24 (24)
$9.0 ($75) 18 (18) 12 (12)
Detectable C-peptide*bF 19 (19) 26 (26) 0.25
Glucose*ϮPb (mg/dL) 161 (106, 221) 176 (122, 237) 0.35
Abnormal creatinine*Ϧ 19 (19) 8 (8) 0.03
Diabetic ketoacidosis requiring
hospitalization in past yearx*
$1 event 7 (7) 2 (2) 0.17
b-Blocker useq 40 (40) 21 (21) 0.006
Variables are shown as n (%), mean 6 SD, or median (25th, 75th percentile). xP value adjusted
for age and random site effect. *Total daily insulin data missing for 13 case and 7 control
subjects; HbA1c data for 1 case subject was excluded due to a falsely low reading as a result of
anemia; creatinine level missing for 2 case subjects; C-peptide missing for 2 case subjects;
glucose data missing for 2 case subjects; diabetic ketoacidosis hospitalization data missing for
1 case subject. ϮP value obtained using continuous variable. PP value adjusted for age,
self-monitoring of blood glucose, and random site effect. bObtained from a random blood
draw at time of C-peptide measurement. FDetectable C-peptide defined as $0.017 nmol/L;
P value adjusted for T1D duration and diagnosis age. ϦAbnormal creatinine defined as
.1.1 mg/dL for females and .1.2 mg/dL for males; P value adjusted for age and T1D
duration. qIncludes oral and ophthalmologic b-blockers; P value adjusted for age and T1D
duration.
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RESULTS
The study included 201 participants
(101 case subjects and 100 control sub-
jects) enrolled between August 2013
and April 2014. Among the case sub-
jects, 33% reported having 1 severe
hypoglycemic event that required
assistance in the past year, 25% reported
2 events, 25% reported 3–9 events, and
18% reported $10 events, with 33%
reporting that the most recent hypogly-
cemic episode resulted in seizure or loss
of consciousness. Among the control
subjects, 33% reported never having
had a severe hypoglycemic event that
required assistance, 22% had an event
3 to,5 years ago, 16% had an event 5 to
,10 years ago, and the remaining 29%
had an event .10 years ago. Fifty-two
percent of case subjects compared with
9% of control subjects reported having
$20 severe hypoglycemic events in the
past (P, 0.001) (Supplementary Table 2).
Demographic, Clinical, and Diabetes
Management Characteristics
Demographics for case and control sub-
jectswere similar formost factors, includ-
ing sex, age, race, diabetes duration,
education, income, and BMI (Table 1).
Similar proportions of case and control
subjects were using an insulin pump
(58% vs. 59%, P = 0.99) tomanage insulin.
Among participants using an insulin
pump, 93% of case and control subjects
had been using a pump for $3 years.
Among participants currently using injec-
tion therapy, 5% of case and control sub-
jects reported using a pump at some
point during the past year. Rapid-acting
insulin analogswere being used by 98%of
those participants who used insulin pump
therapy and by 96% of those who used
injection therapy. This did not differ by
case and control subjects. Total daily in-
sulin amounts were similar (median
0.5 units/kg/day in case and control sub-
jects, P = 0.28). Among case subjects, 51%
reported using an insulin-to-carbohydrate
ratio to decide how much mealtime in-
sulin to take, compared with 41% of
control subjects who used this method.
There was a trend toward more fre-
quent self-reported home blood glucose
meter testing in case subjects compared
with control subjects (mean 6 vs.
5 times/day, respectively; P = 0.02)
(Table 2). For nonglycemic management,
b-blockers were used in 40% of case
subjects and in 21% of control subjects
(P = 0.006). Among those on b-blockers,
there were no differences in selective
versus nonselective b-blocker usage be-
tween case and control subjects (73% of
case subjects vs. 86% of control subjects
were on a selective b-blocker, P = 0.20).
There also were no differences in
b-blocker use between those aware
and those with hypoglycemia unaware-
ness (31% vs. 30%, respectively; P =
0.80). C-peptide levels were detectable
in 19% of case subjects versus 26% of
control subjects (P = 0.25).
Glycemic Measures
Mean HbA1c was 7.8% in case subjects
versus 7.7% in control subjects (P = 0.06)
(Table 2). Mean CGM glucose levels were
similar in case and control subjects
(175 mg/dL [9.7 mmol/L], P = 0.57).
The percentage of time in the range of
70 to 180 mg/dL (51% vs. 52%, respec-
tively; P = 0.26), and .180 mg/dL (42%
vs. 40%, respectively; P = 0.67) was also
similar in both groups. However, there
was a trend toward more time with
CGM glucose level ,60 mg/dL in case
subjects comparedwith control subjects:
4.5% (65min/day) vs. 3.0% (43min/day),
respectively (P = 0.04) (Table 3). This
trend was observed during daytime
(P = 0.01) but not nighttime (P = 0.32).
There also was a trend toward case
subjects more frequently experiencing
Table 3—Blinded CGM data£
Case subjects Control subjects
n = 101 n = 100 P value*
Overall
Mean glucose (mg/dL) 174.9 6 31.6 175.4 6 33.8 0.57
Percentage of time ,70 mg/dL (%) 6.9 (3.4, 12) 5.3 (2.4, 9.3) 0.09
Min/day ,70 mg/dL 99 (49, 173) 76 (34, 134)
Percentage of time ,60 mg/dL (%) 4.5 (1.7, 8.2) 3.0 (1.2, 5.7) 0.04
Min/day ,60 mg/dL 65 (24, 117) 43 (18, 83)
Percentage of time ,50 mg/dL (%) 2.7 (0.7, 5.0) 1.6 (0.6, 3.7) 0.05
Min/day ,50 mg/dL 39 (11, 73) 23 (8, 54)
Percentage of time .180 mg/dL (%) 41.6 (28.2, 53.1) 40.3 (26.9, 58.1) 0.67
Min/day .180 mg/dL 600 (406, 765) 581 (387, 836)
Percentage of time in target range
(70–180 mg/dL) (%)
50.9 (40.6, 62.8) 51.7 (39.1, 61.7) 0.26
Min/day in target range 733 (585, 905) 745 (563, 888)
Glucose variability (%CV) 46.4 (38.8, 50.2) 41.9 (37.0, 45.7) 0.008
Percentage of days with $1
hypoglycemic eventU (%)
46.2 (26.7, 61.5) 33.3 (20.0, 53.3) 0.10
Daytime (6 A.M. to 12 midnight)
Mean glucose (mg/dL) 177.4 6 32.3 178.8 6 33.8 0.66
Percentage of time ,70 mg/dL (%) 7.0 (3.7, 10.6) 4.7 (2.4, 8.0) 0.01
Percentage of time ,60 mg/dL (%) 4.6 (1.8, 7.4) 2.6 (1.2, 4.8) 0.01
Percentage of time ,50 mg/dL (%) 2.4 (0.8, 4.2) 1.3 (0.4, 2.7) 0.02
Percentage of time .180 mg/dL (%) 44.3 (30.3, 54.0) 42.0 (30.1, 55.5) 0.82
Percentage of time in range
(70–180 mg/dL) (%)
49.2 (39.6, 60.0) 51.0 (39.7, 62.2) 0.30
Glucose variability (%CV) 44.9 (38.9, 48.8) 41.2 (36.8, 45.4) 0.004
NighttimeU (12 midnight to 6 A.M.)
Mean glucose (mg/dL) 164.9 6 37.8 164.2 6 42.6 0.50
Percentage of time ,70 mg/dL (%) 7.7 (1.6, 15.2) 6.3 (0.9, 14.6) 0.51
Percentage of time ,60 mg/dL (%) 4.1 (0.7, 11.5) 2.5 (0.0, 9.4) 0.32
Percentage of time ,50 mg/dL (%) 2.2 (0.3, 7.0) 1.2 (0.0, 5.9) 0.19
Percentage of time .180 mg/dL (%) 34.4 (20.6, 49.3) 33.8 (19.3, 50.5) 0.80
Percentage of time in range
(70–180 mg/dL) (%)
54.6 (42.6, 65.6) 55.6 (40.9, 65.0) 0.78
Glucose variability (%CV) 42.2 (35.6, 51.8) 39.9 (33.2, 46.1) 0.03
Values are shown as mean 6 SD or median (25th, 75th percentile). £CGM data missing for
1 control subject and excluded for 1 case subject due to continual acetaminophen use
throughout wear, which affects CGM accuracy; blinded CGM data from subsets of day and
night presented in Supplementary Table 3. *P value adjusted for age and SMBG; rank scores
used to obtain P value. Coefficient of variation (CV) of glucose variability [(SD/mean of
glucose)3 100].UEvent defined as at least 20 min,60 mg/dL; additional CGM data missing for
3 case subjects due to not having the minimum requirement of at least 7 days of data (at
least 6 full h/day). UAdditional CGM data missing for 4 case and 2 control subjects due to less
than 24 h of nighttime CGM readings available.
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periods of hypoglycemia with CGM glu-
cose levels,60mg/dL for$20min (46%
vs. 33% of days with at least one hypo-
glycemic event, respectively; P = 0.10).
The only CGM metric that differed sig-
nificantly between case and control
subjects was glucose variability, as
measured by the coefficient of variation
(P = 0.008), with the difference being
predominantly during the day compared
with the night. When defining high glu-
cose variability as a coefficient of varia-
tion greater than the study cohort’s 75th
percentile (0.481), 38% of case and
12% of control subjects had high glu-
cose variability (P , 0.001).
Cognitive and Functional Testing
Case subjects performed worse than
control subjects on the written version
of the Symbol Digit Modalities Test
(mean 36.5 vs. 41.8, P = 0.001) and
worse on the Trail Making Test–Test B
(median 103 vs. 86 s to complete, P =
0.002) (Table 4). There was a trend for
slightly lower scores in case than in con-
trol subjects on the Montreal Cognitive
Assessment (mean score 25.2 vs. 26.1,
P = 0.04), with over twice as many case
subjects scoring in the impaired range
on this measure (i.e., ,22). There also
was a trend toward less dexterity among
case subjects (P = 0.02). No large differ-
ences were found between case and
control subjects for other cognitive
tests, functional testing, or diabetes
numeracy (Table 4).
Psychosocial Factors
Case and control subjects had similar
depression scores, but there was a trend
for slightly lower scores on the Duke So-
cial Support Scale in case versus control
subjects (mean score 27.5 vs. 28.4, P =
0.04). Case subjects scored higher on
the Hypoglycemia Fear Survey than con-
trol subjects (mean score 38.5 vs. 31.6,
P , 0.001) (Table 4).
Hypoglycemia Unawareness
Case subjects were substantially more
likely than control subjects to have signif-
icant hypoglycemia unawareness (Fig. 1A
and B and Supplementary Table 1). Only
11% of case subjects compared with 43%
of control subjects indicated that they al-
ways had symptoms when blood glucose
was low (P, 0.001), and 17% vs. 6%, re-
spectively, indicated that they never or
rarely had symptoms (P = 0.04). Twenty
percent of case subjects reported not
Table 4—Assessmentsx
Case subjects Control subjects
n = 101 n = 100 P valueV
Montreal Cognitive Assessment*x 25.2 6 3.1 26.1 6 2.8 0.04
,22 16 (16) 7 (7)
22–25 32 (32) 32 (32)
$26 52 (52) 61 (61)
Hopkins Verbal Learning Test–Total
Recall*
22.4 6 5.7 23.2 6 5.0 0.49
,19 27 (27) 17 (17)
19 to ,23 22 (22) 27 (27)
23 to ,27 25 (25) 27 (27)
$27 27 (27) 28 (28)
Hopkins Verbal Learning Test–Delayed
Recall*x
8.0 (6.0, 10.0) 8.5 (7.0, 10.0) 0.35
,6 23 (23) 17 (17)
6 to ,8 19 (19) 17 (17)
8 to ,10 28 (28) 31 (32)
$10 31 (31) 33 (34)
Symbol Digit Modalities Test–Written*x 36.5 6 10.5 41.8 6 10.4 0.001
,32 29 (30) 12 (13)
32 to ,38 30 (31) 24 (25)
38 to ,47 19 (20) 26 (27)
$47 19 (20) 34 (35)
Symbol Digit Modalities Test–Oral*x 42.3 6 11.7 46.8 6 11.0 0.01
,36 27 (28) 15 (16)
36 to ,44 30 (31) 21 (22)
44 to ,52 20 (21) 30 (32)
$52 20 (21) 29 (31)
Trail Making Test–Trail AxϮ 39 (30, 47) 34 (26, 44) 0.06
,27 s 18 (18) 29 (29)
27–35 s 23 (23) 25 (25)
36–45 s 31 (31) 26 (26)
.45 s 29 (29) 20 (20)
Trail Making Test–Trail B*x 103 (79, 140) 86 (66, 111) 0.002
,71 s 18 (18) 29 (30)
71–95 s 21 (21) 30 (31)
96–120 s 28 (28) 21 (22)
.120 s 32 (32) 16 (17)
Grooved Pegboard Test
(Dominant Hand)*xϮ
99 (80, 121) 87 (77, 107) 0.02
,80 s 20 (20) 28 (28)
80 to ,100 s 30 (30) 40 (40)
$100 s 50 (50) 31 (31)
Geriatric Depression Scale*x 1 (0, 2) 1 (0, 3) 0.83
0–5 90 (89) 86 (87)
6–9 7 (7) 10 (10)
$10 4 (4) 3 (3)
Diabetes Numeracy Test*xa 86.7 (66.7, 93.3) 80.0 (66.7, 93.3) 0.58
,70% correct 27 (28) 25 (26)
70 to ,90% correct 34 (35) 33 (34)
$90% correct 37 (38) 40 (41)
Functional Activities Questionnairex 0 (0, 2) 0 (0, 0) 0.85
0 68 (67) 77 (77)
1–8 28 (28) 19 (19)
$9 5 (5) 4 (4)
Hypoglycemia Fear Survey*x 38.5 6 12.8 31.6 6 11.8 ,0.001
,25 17 (17) 34 (34)
25 to ,35 25 (25) 28 (28)
35 to ,45 22 (22) 21 (21)
$45 35 (35) 16 (16)
Preferring Hypoglycemia Scale
(hyperglycemic fear)* 12 (12) 16 (16) 0.42
Continued on p. 608
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feeling symptoms of hypoglycemia until
blood glucose was ,40 mg/dL vs. 3% of
control subjects (P = 0.009).
When defining hypoglycemia un-
awareness as never, rarely, or some-
times having symptoms when blood
glucose is low (as opposed to often or
always having symptoms), 58% of case
subjects and 25% of control subjects had
hypoglycemia unawareness (P, 0.001).
Case subjects were more likely to have a
combination of hypoglycemia unaware-
ness and high glucose variability (as de-
fined above) compared with control
subjects (24% vs. 5%, respectively;
P = 0.003).
CONCLUSIONS
This case-control study of older adults
with long-standing T1D found that the oc-
currence of recent severe hypoglycemia
was associatedwith greater hypoglycemia
unawareness and higher glucose variabil-
ity but not with lower HbA1c or mean
glucose levels. The latter finding indicates
that the risk of severe hypoglycemia in this
age group was not due to tighter glycemic
control. The greater risk also was not due
to less fear of hypoglycemia, and in fact,
those with recent severe hypoglycemia,
not surprisingly, had greater fear of hypo-
glycemia. The slightly higher daily fre-
quency of blood glucose monitoring in
case subjects compared with control sub-
jects might be related to their higher fear
of hypoglycemia. Hypoglycemia unaware-
ness, which is associated with altered
counterregulation, is more common in
older adults with long-duration T1D than
in younger individuals or thosewith type2
diabetes (27). Individualswith reducedhy-
poglycemia awareness are more prone to
severe hypoglycemia and high morbidity
and mortality, particularly in the elderly
(5–7,28). Current insulin therapies are un-
able to eliminate this risk. Routine screen-
ing for hypoglycemia unawareness in this
population is recommended and can be
accomplished using a brief questionnaire
(25). Whether the glucose counterregula-
tory failure that characterizes hypoglyce-
mia unawareness may explain the greater
glucose variability reported here requires
further study, and future work should ex-
plore strategies to correct defective glu-
cose counterregulation in T1D.
The finding of greater glucose vari-
ability in case subjects than in control
subjects is a concern, particularly when
combined with a lack of awareness of
hypoglycemia. Earlier studies examining
limited glucose data from self-monitoring
of blood glucose in younger patients
suggested that blood glucose variance
was related to hypoglycemia (29,30).
A more recent study in long-standing
T1D complicated by reduced awareness
of hypoglycemia showed that glucose
variability as determined by 72-h CGM
was related to the severity of clinically
problematic hypoglycemia (31).
Although the percentages of partici-
pants with measurable C-peptide levels
were not different between the two
groups, single C-peptide measurements
are not as sensitive as provocative test-
ing. Further research is required to de-
termine if endogenous insulin secretion
can assist in explaining our findings.
b-Blockers, which are commonly used
in older patients with diabetes for a va-
riety of indications, were more com-
monly used by case subjects than by
control subjects. In younger age groups
with shorter durations of diabetes than
in our report, the adverse effect of se-
lective and nonselective b-blockers on
hypoglycemia unawareness has been
studied (32,33), although we did not
find an association between hypoglyce-
mia unawareness andb-blocker use.We
also note that there are no data about
hypoglycemia risks in elderly patients
with T1D, although one report of
13,559 subjects with type 2 diabetes
did not find that b-blockers significantly
increased the risk of severe hypoglyce-
mia (34). Use ofb-blockers in that report
included oral and eye drop prepara-
tions, and the indications for use were
not recorded. Further research is needed
tobetter understand thepossible influence
of nonselective b-blocker use on hypogly-
cemia in this population.
The study found some differences in
executive function and psychomotor
processing speed between case and con-
trol subjects. These could be contributory
Table 4—Continued
Case subjects Control subjects
n = 101 n = 100 P valueV
Duke Social Support Scale*x 27.5 6 3.6 28.4 6 3.1 0.04
11–25 23 (23) 15 (15)
26–30 56 (56) 60 (60)
31–33 21 (21) 25 (25)
Frailty 10-Foot Walk*xq 3.3 (3.0, 4.0) 3.0 (3.0, 3.5) 0.01
,3 s 18 (18) 21 (21)
3–4 s 66 (66) 73 (74)
.4 s 16 (16) 5 (5)
Colenbrander Reading CarddLowest
LineF
,20/40 13 (13) 11 (11) 0.28
Values are shown as n (%), mean 6 SD, or median (25th, 75th percentile). §Scoring details:
Montreal Cognitive Assessment, Hopkins Verbal Learning Test, and Symbol Digit Modalities Test
cognitive testsdlower scores indicate reduced capacity; Trail Making and Grooved Pegboard
cognitive testsdhigher scores indicate reduced capacity; Geriatric Depression Scaledhigher
scores indicate increased depression; Diabetes Numeracy Testdlower scores represent
diminishedmathematical skills; Functional Activities Questionnairedhigher scores indicate less
functional independence; Hypoglycemia Fear Surveydhigher scores indicate more
hypoglycemia fear; Duke Social Supportdlower scores indicate reduced support; Frailty
Walkdhigher scores indicate increased physical frailty. Additional scoring details are listed in
the Supplementary Data.VP value adjusted for age and random site effect. *Montreal Cognitive
Assessment data missing for 1 case subject; Hopkins Verbal Learning Test–Total Recall data
missing for 1 control subject and –Delayed Recall data missing for 2 control subjects; Symbol
Digit Modalities Test–Written data missing for 4 case and 4 control subjects and –Oral data
missing for 4 case and 5 control subjects; Trail Making Test–Trail B data missing for 2 case and
4 control subjects; Grooved Pegboard data missing for 1 case and 1 control subject; Geriatric
Depression Scale data missing for 1 control subject; Diabetes Numeracy Test data missing
for 3 case and 2 control subjects; Hypoglycemia Fear Survey data missing for 2 case subjects and
1 control subject; Preferring Hypoglycemia Scale (hyperglycemic fear) data missing for 2 case
subjects; Duke Social Support Index data missing for 1 case subject; Frailty Walk data missing for
1 case and 1 control subject. xP value obtained using continuous variable. ϮDue to extreme
outliers, rank scores used to obtain P value. aP value adjusted for insulin method (pump vs.
injections), in addition to age and site. qP value adjusted for use of assistive devices during the
test, in addition to age and site. FEnglish Continuous Text Near Vision Card; P value obtained
from treating reading vision as an ordinal variable and adjusting for visual aids used during the
test (such as a magnifying glass), in addition to age and site.
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factors for severe hypoglycemia, could re-
sult from recurrent hypoglycemia, or
could be part of a vicious cycle involving
both. Those with cognitive impairment
may be less able to determine and self-
administer the correct insulin doses
(for meals and correction of hypergly-
cemia) and amounts of carbohydrate for
falling glucose levels. They may fail to an-
ticipate the consequences of exercise or
missed meals. This may be particularly
problematic in those who lack physiolog-
ical symptoms to alert them of hypogly-
cemia. Conversely, hypoglycemia could
be related to the development of
these cognitive impairments. No dif-
ferences between case and control sub-
jects were seen in functional activities
score, numeracy, vision testing, depres-
sion, or social support.
A potential limitation of the study is
that participants were from specialized
diabetes centers; however, because
case and control subjects were matched
within centers, this was not likely a
source of bias. Nevertheless, it is possi-
ble that results could differ in patients
meeting study eligibility criteria receiv-
ing care in other settings. There is also
the possibility of survivor bias. Individu-
als with a history ofmore severe hypogly-
cemia could have had earlier mortality.
The study excluded users of CGM at
home because frequency of use in this
age group is low and it would be inappro-
priate to pool data from CGM and
non-CGM users. The number of parti-
cipants (n = 201) is also a limitation, and
the quantity and quality of diabetes edu-
cation they received over their many
years of diabetes is unknown.
Because hypoglycemia is a major
problem in older adults with longstand-
ing T1D, current guidelines suggest
higher HbA1c goals for this population
based on the assumption that this will
lead to less hypoglycemia (9). Our re-
sults suggest that raising HbA1c goals in
many patients will be insufficient to re-
duce severe hypoglycemia in this popu-
lation due to thepresenceof hypoglycemia
unawareness and increased glucose var-
iability. Therefore, until an artificial pan-
creas or b-cell replacement therapy
becomes available, frequent home glu-
cose measurements may be an impor-
tant strategy for these patients. Other
methods to reduce hypoglycemic expo-
sure (35) and minimize b-blocker use
should be considered. The use of current
technologies, such as CGM and thresh-
old suspend pumps, in this population
requires further study.
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